News
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 pounds (15 kilograms). That’s according to the study funded by Lilly, which was published Sunday in the New England Journal of Medicine.
Tirzepatide is more effective than semaglutide for weight loss, according to a new study on GLP-1 medications ; The study was ...
With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...
First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...
The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...
Lose It! on MSN9d
Should I Take a Supplement If I Am on a GLP-1?If you experience symptoms like muscle cramping, irregular or fast heart rate, headaches, fatigue, nausea and vomiting, ...
Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback